Search tips
Search criteria 


Logo of bmjcredLink to Publisher's site
Br Med J (Clin Res Ed). 1982 April 10; 284(6322): 1081–1084.
PMCID: PMC1497956

Survival and desferrioxamine in thalassaemia major.


A small randomised trial and observation of all patients homozygous for beta-thalassaemia in Britain born in or before 1963 indicated that those patients who had received average weekly doses of more than 4 g of desferrioxamine over the previous few years were less likely to die in the near future than were patients of similar ages who had received less, or no, desferrioxamine.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1002K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • SMITH RS. Iron excretion in thalassaemia major after administration of chelating agents. Br Med J. 1962 Dec 15;2(5319):1577–1580. [PMC free article] [PubMed]
  • Barry M, Flynn DM, Letsky EA, Risdon RA. Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress. Br Med J. 1974 Apr 6;2(5909):16–20. [PMC free article] [PubMed]
  • Modell CB, Beck J. Long-term desferrioxamine therapy in thalassemia. Ann N Y Acad Sci. 1974;232(0):201–210. [PubMed]
  • Propper RD, Shurin SB, Nathan DG. Reassessment of the use of desferrioxamine B in iron overload. N Engl J Med. 1976 Jun 24;294(26):1421–1423. [PubMed]
  • Propper RD, Cooper B, Rufo RR, Nienhuis AW, Anderson WF, Bunn HF, Rosenthal A, Nathan DG. Continuous subcutaenous administration of deferoxamine in patients with iron overload. N Engl J Med. 1977 Aug 25;297(8):418–423. [PubMed]
  • Hussain MA, Green N, Flynn DM, Hussein S, Hoffbrand AV. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload. Lancet. 1976 Dec 11;2(7998):1278–1280. [PubMed]
  • Pippard MJ, Letsky EA, Callender ST, Weatherall DJ. Prevention of iron loading in transfusion-dependent thalassaemia. Lancet. 1978 Jun 3;1(8075):1178–1181. [PubMed]
  • Modell B. Advances in the use of iron-chelating agents for the treatment of iron overload. Prog Hematol. 1979;11:267–312. [PubMed]
  • Letsky EA. A controlled trial of long-term chelation therapy in homozygous beta-thalassemia. Birth Defects Orig Artic Ser. 1976;12(8):31–41. [PubMed]
  • Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. [PubMed]
  • Kaye SB, Owen M. Cardiac arrhythmias in thalassaemia major: evaluation of chelation treatment using ambulatory monitoring. Br Med J. 1978 Feb 11;1(6109):342–342. [PMC free article] [PubMed]
  • Hoffbrand AV, Gorman A, Laulicht M, Garidi M, Economidou J, Georgipoulou P, Hussain MA, Flynn DM. Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine. Lancet. 1979 May 5;1(8123):947–949. [PubMed]
  • Henry WL, Nienhuis AW, Wiener M, Miller DR, Canale VC, Piomelli S. Echocardiographic abnormalities in patients with transfusion-dependent anemia and secondary myocardial iron deposition. Am J Med. 1978 Apr;64(4):547–555. [PubMed]

Articles from British Medical Journal (Clinical Research Ed.) are provided here courtesy of BMJ Publishing Group